Colorectal cancer (CRC) is often diagnosed at an advanced stage when tumor cell
dissemination has taken place. Chemo-and targeted therapies provide only a limited …

Simple Summary Chemotherapy, radiotherapy and molecularly targeted therapy could
improve the prognosis of colorectal cancer (CRC) patients. Recently, immunotherapy …

Immune checkpoint inhibitors (ICIs) have marked a new era of cancer treatment, showing
remarkable efficacy in a wide range of solid malignancies. In colorectal cancer (CRC) …

Modulation of the interaction between the immune system and the tumor microenvironment
has long been a target of cancer research, including colorectal cancer (CRC). Approaches …

Immunotherapy using checkpoint inhibitor targeting PD-1 and PD-L1 revolutionized the
treatment of microsatellite instable metastatic colon cancer. Such treatment is now a …

Simple Summary A subset of colorectal cancers (CRCs) is characterized by a mismatch
repair deficiency that is frequently associated with microsatellite instability (MSI). The …

The success of immune checkpoint inhibitors (ICIs) in an increasing range of heavily
mutated tumor types such as melanoma has culminated in their exploration in different …

Immune checkpoint inhibitors have reshaped the prognostic of several tumor types,
including metastatic colorectal tumors with microsatellite instability (MSI). However, 90-95 …

Following initial success in melanoma and lung tumours, immune checkpoint inhibitors
(ICIs) are now well recognized as a major immunotherapy treatment modality for multiple …

Simple Summary More emerging studies are exploring immunotherapy for solid cancers,
including colorectal cancer. Besides, checkpoint blockade immunotherapy and chimeric …